Celsion Corporation Stock Nasdaq
Equities
US15117N4043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.54M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
Latest transcript on Celsion Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Tardugno
CHM | Chairman | 73 | 07-01-02 |
Jeffrey Church
DFI | Director of Finance/CFO | 67 | 10-07-05 |
Sebastien Hazard
CTO | Chief Tech/Sci/R&D Officer | 53 | Dec. 10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-06-07 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 11-07-07 |
James Dentzer
BRD | Director/Board Member | 57 | 22-10-02 |
1st Jan change | Capi. | |
---|---|---|
-2.90% | 103B | |
+1.57% | 95.28B | |
+1.46% | 22.15B | |
-16.14% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.28% | 16.05B | |
+5.54% | 13.68B | |
+33.14% | 12.17B |